Sonoma Pharmaceuticals Historical PE Ratio image   This SNOA PE ratio history page last updated 2/14/2022
Sonoma Pharmaceuticals Historical PE Ratio Chart
Data adjusted for SNOA split history

PeriodPriceGAAPAnnualizedPE
Q3 2022
2/11/2022
3.77-0.31-1.24NA
Q2 2022
11/15/2021
5.60-0.04-0.16NA
Q1 2022
8/16/2021
5.72-0.52-2.08NA
Q4 2021
7/14/2021
7.68-1.64-6.56NA
Q3 2021
2/16/2021
9.64-0.31-1.24NA
Q2 2021
11/20/2020
6.630.080.3220.7
Q1 2021
8/14/2020
7.560.020.0894.5
Q4 2020
7/10/2020
6.44-0.77-3.08NA
Q3 2020
2/14/2020
5.00-0.72-2.88NA
Q2 2020
11/14/2019
5.46-0.91-3.64NA
Q1 2020
8/13/2019
5.40-1.32-5.28NA
Q4 2019
7/8/2019
7.19-2.45-9.80NA
Q3 2019
2/14/2019
6.39-2.34-9.36NA
Q2 2019
11/8/2018
11.79-3.96-15.84NA
Q1 2019
8/8/2018
17.28-4.95-19.80NA
Q4 2018
6/13/2018
36.09-8.37-33.48NA
Q3 2018
2/7/2018
41.76-6.57-26.28NA
Q2 2018
11/9/2017
42.21-6.03-24.12NA
Q1 2018
8/9/2017
53.73-7.38-29.52NA
Q4 2017
6/5/2017
69.75-6.21-24.84NA
Q3 2017
2/9/2017
59.311.626.489.2
Q2 2017
11/10/2016
40.23-4.14-16.56NA
Q1 2017
7/28/2016
42.66-4.50-18.00NA
Q4 2016
6/16/2016
8.73-1.26-5.04NA
Q3 2016
2/4/2016
11.16-1.35-5.40NA
Q2 2016
11/5/2015
10.98-0.99-3.96NA
Q1 2016
7/30/2015
15.93-1.35-5.40NA
Q4 2015
6/11/2015
15.57-0.99-3.96NA
Q3 2015
2/12/2015
7.29-1.35-5.40NA
Q2 2015
11/12/2014
15.30-0.72-2.88NA
Q1 2015
8/7/2014
23.49-0.09-0.36NA
Q4 2014
6/12/2014
29.618.9135.640.8
Q3 2014
2/13/2014
28.98-0.81-3.24NA
Q2 2014
11/19/2013
22.14-1.89-7.56NA
Q1 2014
8/8/2013
24.12-2.34-9.36NA
Q4 2013
6/13/2013
32.76-3.96-15.84NA
Sonoma Pharmaceuticals PE History Chart
PeriodPriceGAAPTTMPE
Q3 2022
2/11/2022
3.77-0.31-2.51NA
Q2 2022
11/15/2021
5.60-0.04-2.51NA
Q1 2022
8/16/2021
5.72-0.52-2.39NA
Q4 2021
7/14/2021
7.68-1.64-1.85NA
Q3 2021
2/16/2021
9.64-0.31-0.98NA
Q2 2021
11/20/2020
6.630.08-1.39NA
Q1 2021
8/14/2020
7.560.02-2.38NA
Q4 2020
7/10/2020
6.44-0.77-3.72NA
Q3 2020
2/14/2020
5.00-0.72-5.40NA
Q2 2020
11/14/2019
5.46-0.91-7.02NA
Q1 2020
8/13/2019
5.40-1.32-10.07NA
Q4 2019
7/8/2019
7.19-2.45-13.70NA
Q3 2019
2/14/2019
6.39-2.34-19.62NA
Q2 2019
11/8/2018
11.79-3.96-23.85NA
Q1 2019
8/8/2018
17.28-4.95-25.92NA
Q4 2018
6/13/2018
36.09-8.37-28.35NA
Q3 2018
2/7/2018
41.76-6.57-26.19NA
Q2 2018
11/9/2017
42.21-6.03-18.00NA
Q1 2018
8/9/2017
53.73-7.38-16.11NA
Q4 2017
6/5/2017
69.75-6.21-13.23NA
Q3 2017
2/9/2017
59.311.62-8.28NA
Q2 2017
11/10/2016
40.23-4.14-11.25NA
Q1 2017
7/28/2016
42.66-4.50-8.10NA
Q4 2016
6/16/2016
8.73-1.26-4.95NA
Q3 2016
2/4/2016
11.16-1.35-4.68NA
Q2 2016
11/5/2015
10.98-0.99-4.68NA
Q1 2016
7/30/2015
15.93-1.35-4.41NA
Q4 2015
6/11/2015
15.57-0.99-3.15NA
Q3 2015
2/12/2015
7.29-1.356.751.1
Q2 2015
11/12/2014
15.30-0.727.292.1
Q1 2015
8/7/2014
23.49-0.096.123.8
Q4 2014
6/12/2014
29.618.913.877.7
Q3 2014
2/13/2014
28.98-0.81-9.00NA
Q2 2014
11/19/2013
22.14-1.89NANA
Q1 2014
8/8/2013
24.12-2.34NANA
Q4 2013
6/13/2013
32.76-3.96NANA
Quotes delayed 20 minutes

Email EnvelopeFree SNOA Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Sonoma Pharmaceuticals (SNOA) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

SNSE PE Ratio History
SOLY PE Ratio History
SONN PE Ratio History
SPNE PE Ratio History
SPPI PE Ratio History
SPRB PE Ratio History
SPRO PE Ratio History
SQZ PE Ratio History
SRDX PE Ratio History
SRGA PE Ratio History
How should the SNOA historical PE ratio be determined?
Realizing that PE stands for Price to Earnings ratio, we need two values to compute it: stock price and earnings per share. The stock price at any given date is a known historical value, but what about the earnings number to use?

✔️Accepted answer: There are a number of different approaches when it comes to calculating a historical PE ratio for a company like Sonoma Pharmaceuticals. We like to take our measurements on each of the past quarterly earnings reports. That only leaves the question of whether the earnings number at that quarterly report should be used on an annualized basis, or some other method. We approach this question using three different methods, on this SNOA Historical PE Ratio page.

What is the average historical PE for SNOA based on annualized quarterly earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use that quarter's earnings result annualized?

✔️Accepted answer: The SNOA historical PE ratio using the annualized quarterly earnings method works out to 31.3.

What is the average historical PE for SNOA based on trailing twelve month earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the trailing twelve months combined earnings result in the calculation?

✔️Accepted answer: The SNOA historical PE ratio using the TTM earnings method works out to 3.7.

On this page we presented the Sonoma Pharmaceuticals Historical PE Ratio information for Sonoma Pharmaceuticals' stock. The average SNOA historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 31.3. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average SNOA historical PE based on this TTM earnings result method is 3.7. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this SNOA historical PE result, against the recent PE: when this page was posted on 2/11/2022, the most recent closing price for SNOA had been 3.77, and the most recent quarterly earnings result, annualized, was 0.32. Meanwhile, the most recent TTM earnings summed to 6.75. From these numbers, we calculate the recent SNOA PE on 2/11/2022 based on annualized quarterly EPS was 11.8. Based on SNOA's history, that recent PE is low relative to the historical average, with the recent PE 62.3% lower than the historical average PE across our data set for Sonoma Pharmaceuticals. Looking at the recent SNOA PE on 2/11/2022 based on TTM EPS, we calculate the ratio at 0.6. Based on SNOA's history, that recent PE is low relative to the historical average, with the recent PE 83.8% lower than the average PE across our Sonoma Pharmaceuticals data set with TTM EPS used in the calculation at each period.

For self directed investors doing their due diligence on SNOA or any other given stock, valuation analysis for SNOA can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Sonoma Pharmaceuticals PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for SNOA. Thanks for visiting, and the next time you need to research SNOA Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.

Recommended: KMX market cap history, IWL market cap history, Institutional Holders of RAAS.

 

Sonoma Pharmaceuticals Historical PE Ratio | www.HistoricalPERatio.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.